ella

Quick links to important sections

ella

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of ella

Quick Facts

Property Description
Active ingredient Ulipristal Acetate
Form Oral Tablet
Pharmacological class Selective Progesterone Receptor Modulator (SPRM)
Common use Emergency Contraception (Prevention of Pregnancy)
Origin Synthetic Steroid Derivative

What is the Drug ella and Its Classification?

The medicine known commercially as ella is a prescription-only drug, available as a single-ingredient oral tablet, whose active component is Ulipristal Acetate. This compound is formally classified as an emergency contraceptive, specifically intended for time-sensitive use following events such as unprotected sexual intercourse or when a regular contraceptive method fails. Its pharmacological identity is defined by its membership in the class of selective progesterone receptor modulators (SPRM).

The foundational identity of the product is rooted in its classification, which dictates its singular general purpose: the prevention of pregnancy. ella is recognized as a distinctive emergency measure due to the Ulipristal Acetate's ability to maintain efficacy for up to 120 hours (five days) post-coitus. This extended time frame is a clinically recognized advantage over some older progestin-only alternatives, providing women with a broader window for intervention.

Ulipristal Acetate: Composition, Origin, and Primary Purpose

Ulipristal Acetate is a synthetic steroid derivative that serves as the sole active pharmaceutical ingredient. As a single-ingredient product, it is formulated within a standard solid oral tablet matrix designed for systemic absorption. The synthetic nature of the compound ensures a predictable and potent interaction with the hormonal system.

The primary function of this composition is to prevent conception: the active ingredient acts by selectively modulating progesterone receptors to delay or inhibit the release of an egg (ovulation) from the ovary. This time-critical action is categorized as non-abortifacient, meaning its preventive function occurs strictly before fertilization and implantation can take place, focusing entirely on intervening in the possibility of conception.

Regulatory References

  1. [pharmacological studies published by the European Medicines Agency]
  2. [as confirmed by the National Institutes of Health](https://pubmed.ncbi.nlm.nih.gov/26038891)
  3. [by the Food and Drug Administration (FDA)]

What side effects are possible with ella?

Possible side effects and safety information for ella (Ulipristal Acetate)

Official regulatory documents classify the potential side effects of Ulipristal Acetate (ella) based on their observed frequency in clinical studies, and map them to physiological systems.


Frequency-Classified Adverse Reactions

The most frequently documented side effects are categorized as Very Common or Common according to regulatory standards:

Classification Examples of Reactions
Very Common (ge 1/10) Headache, Nausea, Abdominal pain (including upper abdominal pain).
Common (ge 1/100 to < 1/10) Dizziness, Dysmenorrhea (painful menstruation), Fatigue, Vomiting, Mood disorders, Breast tenderness.

Adverse effects are primarily grouped under Gastrointestinal Disorders (e.g., nausea, vomiting) and Nervous System Disorders (e.g., headache, dizziness). The effects on the Reproductive System include expected alterations to the next menstrual cycle, which may occur earlier or later than anticipated.


Serious Adverse Reactions and Safety Constraints

Specific safety concerns are highlighted in the official prescribing information. The possibility of an Ectopic Pregnancy must be considered if the medication fails to prevent conception. Post-marketing reports also include isolated cases of Hepatic Injury/Failure, though this concern is primarily associated with the long-term, higher-dose Ulipristal Acetate formulation.

Safety constraints define populations where use is restricted or not recommended. The medication is contraindicated if an existing pregnancy is confirmed. Use is not recommended in individuals with severe hepatic impairment or severe renal impairment due to a lack of safety data. Additionally, the drug is intended for occasional emergency use only and should not be used repeatedly within the same menstrual cycle.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory data indicates that clinical experience with Ulipristal Acetate overdose is limited. However, single doses equivalent to up to four times the recommended dose and doses up to 200 mg were administered in studies and reported as well-tolerated without resulting in severe or life-threatening adverse reactions.

Documented Overdose Manifestations

The effects observed in cases of documented high-dose exposure relate primarily to the menstrual cycle. These include a shortened menstrual cycle (with uterine bleeding occurring earlier than expected) and prolonged duration of bleeding described as spotting.


Emergency Actions and Required Management

Action Domain Regulatory Statement
Seeking Urgent Help Seek emergency medical attention for any suspected overdose. Contact the Poison Help line (e.g., 1-800-222-1222) for guidance.
Life-Threatening Signs Call emergency services if the person has collapsed, had a seizure, has trouble breathing, or can't be awakened.
Antidote Status No specific antidotes are known or available for Ulipristal Acetate overdose.
Treatment Mandate Further treatment should be symptomatic and supportive.

This required response framework defines the necessary actions to ensure professional triage and supportive care, given the absence of a specific pharmacological antidote and the limited, non-severe manifestations documented in official regulatory summaries.

Therapeutic Uses of ella

What ella Treats: Main Uses and Benefits

The focus of ella (Ulipristal Acetate) is generally on providing short-term symptomatic assistance to help address the risk associated with potential pregnancy, and it is used in acute contexts for post-event control to address the risk of conception.

This highly specific therapeutic application is generally applied in clinical scenarios involving unplanned sexual contact, known or suspected lapse in primary contraception (such as a missed oral tablet or device failure), and situations requiring post-event control. These uses are relevant when a failure leads to a state of heightened reproductive risk, and the medication may assist with maintaining functional stability by providing a back-up measure that contributes to easing the overall symptom load related to unwanted pregnancy risk. A primary benefit of the medication supports the patient during difficult episodes regarding its use for intervention over an extended period following the event.

“This application window may assist those who need greater flexibility or time to access medical care, providing supportive relief regarding their reproductive status during this critical period.”


Quick Fact: Relief for Conception Risk

Property Description
Primary Use Acute therapeutic assistance following unplanned sexual contact.
Scenario Focus Used for addressing a lapse in contraception.
Patient Benefit Contributes to supportive relief and helps ease the burden of uncertainty.
Time Frame Advantage Is considered relevant for intervention for an extended period following the event.

Regulatory References

  1. NIH MedlinePlus Drug Information on Ulipristal

Eligibility and Restrictions for Use

Who Can and Cannot Use ella? (Ulipristal Acetate)

The population eligibility for ella is strictly defined by official regulatory documentation, establishing who may use the medicine and who is prohibited or restricted from use. This information is based on formal regulatory classifications.


Absolute Non-Eligibility (Contraindications)

The medicine is formally contraindicated and must not be used by women with a known or suspected pregnancy. Use is also strictly prohibited in patients with a hypersensitivity to the active substance or any of the tablet's excipients. Patients with rare hereditary disorders such as galactose intolerance or Lapp lactase deficiency should also not take the medicine due to excipient content.


Regulatory Use Restrictions

The regulatory label establishes a "not recommended" status for certain populations. This includes women with severe hepatic impairment or severe asthma insufficiently controlled by oral glucocorticoids. The label also advises against repeated use within the same menstrual cycle. For lactating women, official guidance recommends interrupting or suspending breastfeeding for one week after taking the tablet.


Age and Development Status

Use is intended exclusively for women of reproductive age, including postpubertal adolescents. The medicine is officially not intended for use in premenarcheal or postmenopausal females. Safety and efficacy have not been evaluated in women aged 65 and older.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ulipristal Acetate (ella) exhibits officially documented interaction patterns centered on metabolic interference and pharmacodynamic antagonism, as classified by regulatory authorities.

The most critical pharmacokinetic interaction involves substances that are strong inducers of the CYP3A4 hepatic enzyme. Co-administration with these inducers, such as Rifampin and certain anticonvulsants like Carbamazepine and Phenytoin, is formally advised against. This is due to a drastic reduction in Ulipristal Acetate plasma exposure; for instance, Rifampin has been documented to decrease the drug's AUC by approximately 93%, an outcome that may lead to significantly reduced efficacy. Herbal products that induce this enzyme, such as St. John's Wort, are similarly classified as substances that must be avoided.

A significant pharmacodynamic restriction exists with other progestin-containing products, including combined hormonal contraceptives. Ulipristal Acetate's high-affinity binding to the progesterone receptor may impair the intended action of these methods. Regulatory documentation mandates a strict timing separation: the initiation or resumption of any hormonal contraceptive method must be delayed for no less than 5 days following the intake of ella. Additionally, simultaneous use with other emergency contraceptives, such as those containing Levonorgestrel, is formally not recommended. Though a high-fat meal is documented to alter the absorption rate (Cmax), administration can occur with or without food.

Mechanism of Action

Selective Progesterone Receptor Modulation

The drug's core action is defined by its role as a Selective Progesterone Receptor Modulator (SPRM). It exerts its effect by binding to the body's progesterone receptors (PR) located in various endocrine tissues, thereby altering the typical hormonal signaling. This molecular interaction initiates the cascade that influences the central hormonal control of the reproductive cycle.


Central Inhibition of the LH Surge

This modulation of PR activity in the central endocrine system leads to the most significant physiological consequence: the suppression or delay of the Luteinizing Hormone (LH) surge. This hormonal blockade acts to suppress the rupture of the ovarian follicle, which is associated with the inhibition or delay of ovulation.


Modification of the Uterine Lining

The drug also interacts with PR located in peripheral tissues, specifically the endometrium (the tissue lining the uterus). This local interaction influences cellular structure and differentiation, resulting in a modification of the endometrial tissue's characteristics.

Dosage and Administration Information

How ella is Used

The administration of ella (ulipristal acetate) is defined by its use as a single-dose, time-critical intervention. The established route of administration is oral, consisting of a single 30 mg tablet. This dosage constitutes the entire standard adult regimen for its intended context, and it is not intended for routine or repeated use within the same menstrual cycle.


Administration Timing and Context

The critical principle for administration is promptness, with the tablet required to be taken as soon as possible, and in any event, no later than 120 hours (five days) following the event of concern. The tablet may be administered with or without food, and it can be taken at any time during the menstrual cycle, providing flexibility necessary for time-sensitive use.

Standard procedure for managing potential non-absorption includes a specific step: if vomiting occurs within 3 hours of taking the tablet, an additional 30 mg dose should be considered. For individuals who wish to initiate or resume a regular hormonal contraceptive method, there is a specified waiting period: the hormonal method should not be started or resumed until 5 days after the intake of ulipristal acetate, with a barrier method advised for use during the interim. For patients with severe hepatic impairment, specific dose recommendations are not available.

Recent Clinical Evidence

Recent Clinical Evidence

ella (ulipristal acetate) is an oral emergency contraceptive (EC) effective when used up to 120 hours (five days) after unprotected intercourse. Clinical trials primarily focus on two areas: efficacy in preventing pregnancy and effects related to the menstrual cycle.


Efficacy Studies

Clinical trials have established the effectiveness of ulipristal acetate, reporting an overall observed pregnancy rate of approximately 1.9% among participants. This rate was found to be statistically lower than the expected pregnancy rate in the absence of any EC. Research consistently suggests that ulipristal acetate maintains consistent efficacy across the full 120-hour window, which is longer than the traditional 72-hour window studied for some other hormonal ECs.

An analysis of pooled data has also explored the risk of pregnancy in relation to body mass index (BMI). While the effectiveness of hormonal ECs, including ulipristal acetate, may be attenuated in individuals with a higher BMI (over 30 kg/m^2), clinical research does not support dose adjustment based on body size. Further studies are ongoing to confirm the clinical significance of weight in EC outcomes.


Effects on the Menstrual Cycle and Safety Profile

Following the administration of ulipristal acetate, the timing of the subsequent menstrual period may be altered. In clinical trials, the mean cycle length was observed to increase by a few days, though it typically returned to the individual’s normal cycle in the following month. Approximately 19% of study participants reported a delay of more than seven days in the onset of their expected menses.

Adverse Events: The most common adverse reactions reported in the trials, occurring in 10% or more of users, included headache, nausea, and abdominal pain. These effects were generally mild to moderate in severity and resolved spontaneously.

Frequently Asked Questions (FAQ)

Common questions about ella (FAQ)

Q: How does ella relate to the medicine called Plan B?

A: Official information describes ella (ulipristal acetate) as a type of emergency contraception that can be used up to 120 hours (five days) after unprotected intercourse. This is a longer window of use than the traditional 72-hour window associated with some other hormonal emergency contraceptives, such as those that contain levonorgestrel (often sold under brand names like Plan B).

Q: Can certain anti-seizure medicines affect how ella works?

A: Yes, official documents advise that the effectiveness of ella can be reduced if it is taken with certain anti-seizure medicines. These medicines are known to increase the activity of the CYP3A4 enzyme in the liver, which causes ulipristal acetate to be cleared from the body too quickly. Regulatory bodies recommend avoiding co-administration with these types of strong enzyme-inducing medicines.

Q: Is there a change in how ella works for women with a higher BMI?

A: Studies and official information indicate that the effectiveness of emergency contraceptives, including ella, may be attenuated (reduced) in individuals with a higher body mass index (BMI), specifically over 30 kg/m^2. However, regulatory labels currently state that a dose adjustment based on body size is not supported by the available data.

Q: Can ella be used by women who are breastfeeding?

A: Official guidance recommends interrupting or suspending breastfeeding for one week after taking the tablet. This recommendation is given because the active ingredient, ulipristal acetate, can pass into breast milk during this period.

Q: How quickly does ella start working in the body?

A: The action of the drug begins very quickly after it is taken. It starts by binding to progesterone receptors, which rapidly leads to the suppression or delay of the Luteinizing Hormone (LH) surge. This hormonal action is the first step in the proposed mechanism to prevent pregnancy.

Q: What is the chemical name for the active ingredient in ella?

A: The medicine contains the single active ingredient known as Ulipristal Acetate. This compound is chemically classified as a synthetic steroid derivative.

Q: Are there studies comparing the evidence for ella to other options?

A: Yes, regulatory-cited clinical research includes studies that have been conducted to compare the effectiveness and safety profile of ulipristal acetate to other available emergency contraceptive options, most commonly those containing levonorgestrel.

Q: Does ella work to stop a pregnancy that has already occurred?

A: The official position is that ella is formally contraindicated if a woman is already pregnant or suspected to be pregnant. Its action is to prevent pregnancy from occurring by intervening before fertilization or implantation; it is classified as non-abortifacient.

Q: Is it true that ella’s effectiveness remains stable over the full 120 hours?

A: Yes, official clinical trials indicate that ella maintains a consistent level of effectiveness throughout the entire 120-hour (five-day) post-coital window. This consistent efficacy is a key finding in the evidence for the medication.

Q: Is ella used for regular birth control?

A: No. Official regulatory documents strictly state that ella is intended only for emergency contraception. It is not approved and not recommended for routine use as a regular contraceptive method.

Q: Does taking ella affect future fertility?

A: Regulatory information indicates that a rapid return of fertility is likely following the single dose of ella. Official documents address that patients may resume or initiate a regular form of contraception as soon as the official waiting period has passed.

Q: Does ella work if I have already ovulated?

A: The drug's primary function is to delay or inhibit the release of an egg (ovulation). Studies cited in regulatory reviews suggest that once the Luteinizing Hormone (LH) surge has already reached its peak, ella is not expected to have an effect on ovulation.

Q: How long does ella stay in the body after it is taken?

A: After a single dose, the active ingredient, ulipristal acetate, is metabolized in the body. Its main active form has an elimination half-life of approximately 32 hours, meaning it takes about that long for half of the dose to be cleared from the system.

Q: Why is ella sometimes described as a progesterone receptor modulator?

A: ella is classified as a Selective Progesterone Receptor Modulator (SPRM) because of its precise mechanism of action. It works by binding to the body's progesterone receptors (PR), where it alters normal hormonal signaling to prevent pregnancy.

Q: What information should I know about ella and liver issues?

A: Official information states that ella is not recommended for use in women with severe hepatic (liver) impairment due to a lack of safety data. While post-marketing reports for a different, long-term use of ulipristal acetate include serious liver injury, no cases of serious liver injury have been reported with the single-dose emergency contraceptive formulation.

Q: Can ella interact with grapefruit juice?

A: Pharmacokinetic data suggests that grapefruit juice, which can inhibit the CYP3A4 enzyme responsible for drug metabolism, may increase the concentration of ulipristal acetate in the plasma. For the single-dose emergency use, this interaction is generally noted as not likely to be clinically significant.

Q: Are there any long-term side effects associated with ella use?

A: Official guidance states that ella is strictly intended for occasional emergency use and is not intended for routine or long-term use. The adverse reactions listed in the official documents are based on the outcomes of short-term clinical trials.

Q: What should I do if my period is much lighter or heavier than usual after taking ella?

A: Changes to the menstrual cycle are an expected effect of the medication. Official information indicates that if the expected menses is delayed by more than a week, it is important to rule out the possibility of pregnancy. If an altered bleeding pattern is persistent, unexpected, or causes concern, regulatory documents mention consulting a healthcare provider.

Q: What kind of specialist is usually involved in prescribing ella?

A: In regions where it is a prescription-only drug, ella is generally prescribed by licensed healthcare professionals. This typically includes OB-GYN providers or primary care providers who are authorized to write prescriptions.

Q: Can I drive or operate machinery after taking ella?

A: Some common side effects reported in clinical trials include dizziness and fatigue. Regulatory information indicates that if a patient experiences these effects, caution regarding driving or operating machinery is appropriate until the effects subside.

Q: Does ella contain estrogen?

A: No. ella is a single-ingredient medicine containing only Ulipristal Acetate. It is classified as a Selective Progesterone Receptor Modulator (SPRM) and does not contain estrogen.

Q: What are the legal classifications of ella in different countries?

A: The legal status of ulipristal acetate is determined by national regulatory agencies and varies by region. For instance, official decisions classify it as prescription-only in the United States, but it has been made available over-the-counter (OTC) in many countries within the European Union.

Q: Is ella available without a prescription in some places?

A: Yes. While it is classified as a prescription-only drug in some regions like the United States, regulatory decisions in many countries, particularly within the European Union, have made ella (ulipristal acetate) available over-the-counter (OTC).

Q: Does ella have any known impact on mood or mental health?

A: Official regulatory documents classify 'Mood Disorders' as a common adverse reaction, which means it was reported by ge 1/100 to < 1/10 of users in clinical trials. This is an officially recognized potential effect.

Q: What information should I know about ella and kidney issues?

A: Official product information states that ella is not recommended for use in women with severe renal (kidney) impairment. This is a restriction based on the current lack of sufficient safety and efficacy data in this specific population.

Q: Is ella the same thing as the medicine called ulipristal?

A: The medicine is known by the commercial name ella and contains the active substance Ulipristal Acetate. While Ulipristal refers to the base compound, Ulipristal Acetate is the active form that is specifically used in the medication.

How should ella be stored and disposed of?

The medicine ella (ulipristal acetate) must be stored strictly according to the conditions defined in official regulatory documents to maintain its stability.

Official Storage Requirements

Item Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and keep from freezing.
Protection Must be stored in the original carton and blister packaging to protect the tablet from light and moisture.
Child Safety The product must be stored out of the sight and reach of children.

Disposal

When the medicine is no longer needed or has expired, it must not be thrown into household trash or wastewater. Unused or outdated ella should be disposed of through a medicine take-back program or as directed by a healthcare professional in accordance with local disposal regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of ella found in:

A-Z Index: